{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T09:59:27Z","timestamp":1790762367956,"version":"4.1.0"},"reference-count":35,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,6,24]],"date-time":"2024-06-24T00:00:00Z","timestamp":1719187200000},"content-version":"am","delay-in-days":359,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bioorganic & Medicinal Chemistry Letters"],"published-print":{"date-parts":[[2023,7]]},"DOI":"10.1016\/j.bmcl.2023.129384","type":"journal-article","created":{"date-parts":[[2023,6,18]],"date-time":"2023-06-18T17:30:48Z","timestamp":1687109448000},"page":"129384","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":26,"special_numbering":"C","title":["A synthetic lethal approach to drug targeting of G-quadruplexes based on CX-5461"],"prefix":"10.1016","volume":"91","author":[{"given":"Meiyu","family":"Jin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurence H.","family":"Hurley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8341-5409","authenticated-orcid":false,"given":"Hong","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bmcl.2023.129384_b0005","doi-asserted-by":"crossref","first-page":"2027","DOI":"10.1021\/jm00129a001","article-title":"DNA and associated targets for drug design","volume":"32","author":"Hurley","year":"1989","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmcl.2023.129384_b0010","doi-asserted-by":"crossref","unstructured":"McLuckie KI, Di Antonio M, Zecchini H, Xian J, Caldas C, Krippendorff BF, et al. G-quadruplex DNA as a molecular target for induced synthetic lethality in cancer cells. J Am Chem Soc 2013; 135: 9640\u20139643; PMC3964824.","DOI":"10.1021\/ja404868t"},{"key":"10.1016\/j.bmcl.2023.129384_b0015","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1038\/334364a0","article-title":"Formation of parallel four-stranded complexes by guanine-rich motifs in DNA and its implications for meiosis","volume":"334","author":"Sen","year":"1988","journal-title":"Nature"},{"key":"10.1016\/j.bmcl.2023.129384_b0020","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1038\/342825a0","article-title":"Telomeric DNA dimerizes by formation of guanine tetrads between hairpin loops","volume":"342","author":"Sundquist","year":"1989","journal-title":"Nature."},{"key":"10.1016\/j.bmcl.2023.129384_b0025","doi-asserted-by":"crossref","first-page":"2113","DOI":"10.1021\/jm970199z","article-title":"Inhibition of human telomerase by a G-quadruplex-interactive compound","volume":"40","author":"Sun","year":"1997","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmcl.2023.129384_b0030","doi-asserted-by":"crossref","unstructured":"Siddiqui-Jain A, Grand CL, Bearss DJ, Hurley LH. Direct evidence for a G-quadruplex in a promoter region and its targeting with a small molecule to repress c-MYC transcription. Proc Natl Acad Sci USA 2002; 99: 11593\u201311598; PMC129314.","DOI":"10.1073\/pnas.182256799"},{"key":"10.1016\/j.bmcl.2023.129384_b0035","first-page":"103","article-title":"Design and synthesis of fluoroquinophenoxazines that interact with human telomeric G-quadruplexes and their biological effects","volume":"1","author":"Duan","year":"2001","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.bmcl.2023.129384_b0040","doi-asserted-by":"crossref","first-page":"1418","DOI":"10.1158\/0008-5472.CAN-10-1728","article-title":"Targeting RNA polymerase I with an oral small molecule CX-5461 inhibits ribosomal RNA synthesis and solid tumor growth","volume":"71","author":"Drygin","year":"2011","journal-title":"Cancer Res"},{"key":"10.1016\/j.bmcl.2023.129384_b0045","doi-asserted-by":"crossref","first-page":"7653","DOI":"10.1158\/0008-5472.CAN-09-1304","article-title":"Anticancer activity of CX-3543: a direct inhibitor of rRNA biogenesis","volume":"69","author":"Drygin","year":"2009","journal-title":"Cancer Res"},{"key":"10.1016\/j.bmcl.2023.129384_b0050","unstructured":"Jin CH, Rice WG, Siddiqui-Jain A. In vivo efficacy of CX-3543, a novel c-Myc oncogene inhibitor. In 95th Annual Meeting, Am Assoc Cancer Res Vol Abstr LB\u2010243, Orlando, Florida, 2004."},{"key":"10.1016\/j.bmcl.2023.129384_b0055","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1158\/2159-8290.CD-18-1455","article-title":"First-in-human RNA polymerase I transcription inhibitor CX-5461 in patients with advanced hematologic cancers: results of a phase I dose-escalation study","volume":"9","author":"Khot","year":"2019","journal-title":"Cancer Discov"},{"key":"10.1016\/j.bmcl.2023.129384_b0060","doi-asserted-by":"crossref","unstructured":"Bossaert M, Pipier A, Riou JF, Noirot C, Nguy\u00ean LT, Serre RF, et al. Transcription-associated topoisomerase 2\u03b1 (TOP2A) activity is a major effector of cytotoxicity induced by G-quadruplex ligands. Elife 2021; 10: ; PMC8279764.","DOI":"10.7554\/eLife.65184"},{"key":"10.1016\/j.bmcl.2023.129384_b0065","doi-asserted-by":"crossref","unstructured":"Bruno PM, Lu M, Dennis KA, Inam H, Moore CJ, Sheehe J, et al. The primary mechanism of cytotoxicity of the chemotherapeutic agent CX-5461 is topoisomerase II poisoning. Proc Natl Acad Sci USA 2020; 117: 4053\u20134060; PMC7049172.","DOI":"10.1073\/pnas.1921649117"},{"key":"10.1016\/j.bmcl.2023.129384_b0070","doi-asserted-by":"crossref","unstructured":"Olivieri M, Cho T, \u00c1lvarez-Quil\u00f3n A, Li K, Schellenberg MJ, Zimmermann M, et al. A genetic map of the response to DNA damage in human cells. Cell. 2020; 182: 481\u2013496.e421; PMC7384976.","DOI":"10.1016\/j.cell.2020.05.040"},{"key":"10.1016\/j.bmcl.2023.129384_b0075","doi-asserted-by":"crossref","unstructured":"Pan M, Wright WC, Chapple RH, Zubair A, Sandhu M, Batchelder JE, et al. The chemotherapeutic CX-5461 primarily targets TOP2B and exhibits selective activity in high-risk neuroblastoma. Nat Commun 2021; 12: 6468; PMC8578635.","DOI":"10.1038\/s41467-021-26640-x"},{"key":"10.1016\/j.bmcl.2023.129384_b0080","doi-asserted-by":"crossref","unstructured":"Xu H, Di Antonio M, McKinney S, Mathew V, Ho B, O'Neil NJ, et al. CX-5461 is a DNA G-quadruplex stabilizer with selective lethality in BRCA1\/2 deficient tumours. Nat Commun 2017; 8: 14432; PMC5321743.","DOI":"10.1038\/ncomms14432"},{"key":"10.1016\/j.bmcl.2023.129384_b0085","unstructured":"Hilton J, Gelmon K, Cescon D, Tinker A, Jonker D, Goodwin R, et al. CCTG IND.231: A phase I trial evaluating CX-5461, a novel first-in-class G-quadruplex stabilizer in patients with advanced solid tumours enriched for DNA-repair deficiencies. In San Antonio Breast Cancer Symposium, San Antonio, Texas; 2019."},{"key":"10.1016\/j.bmcl.2023.129384_b0090","first-page":"PMC9232501","article-title":"Results of the phase I CCTG IND.231 trial of CX-5461 in patients with advanced solid tumors enriched for DNA-repair deficiencies","volume":"13: 3607","author":"Hilton","year":"2022","journal-title":"Nat Commun"},{"key":"10.1016\/j.bmcl.2023.129384_b0095","doi-asserted-by":"crossref","unstructured":"Bender A, Pringle JR. Use of a screen for synthetic lethal and multicopy suppressee mutants to identify two new genes involved in morphogenesis in Saccharomyces cerevisiae. Mol Cell Biol 1991; 11: 1295\u20131305; PMC369400.","DOI":"10.1128\/MCB.11.3.1295"},{"key":"10.1016\/j.bmcl.2023.129384_b0100","doi-asserted-by":"crossref","unstructured":"Dobzhansky T. Genetics of natural populations; recombination and variability in populations of Drosophila pseudoobscura. Genetics 1946; 31: 269\u2013290; PMC1209328.","DOI":"10.1093\/genetics\/31.3.269"},{"key":"10.1016\/j.bmcl.2023.129384_b0105","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1126\/science.1056072","article-title":"Principles for the buffering of genetic variation","volume":"291","author":"Hartman","year":"2001","journal-title":"Science"},{"key":"10.1016\/j.bmcl.2023.129384_b0110","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1038\/nature03443","article-title":"Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase","volume":"434","author":"Bryant","year":"2005","journal-title":"Nature"},{"key":"10.1016\/j.bmcl.2023.129384_b0115","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1038\/nature03445","article-title":"Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy","volume":"434","author":"Farmer","year":"2005","journal-title":"Nature."},{"key":"10.1016\/j.bmcl.2023.129384_b0120","doi-asserted-by":"crossref","unstructured":"Croft D, Mundo AF, Haw R, Milacic M, Weiser J, Wu G, et al. The Reactome pathway knowledgebase. Nucleic Acids Res. 2014; 42: D472\u2013D477; PMC3965010.","DOI":"10.1093\/nar\/gkt1102"},{"key":"10.1016\/j.bmcl.2023.129384_b0125","doi-asserted-by":"crossref","unstructured":"Hodge CD, Spyracopoulos L, Glover JN. Ubc13: the Lys63 ubiquitin chain building machine. Oncotarget. 2016; 7: 64471\u201364504; PMC5325457.","DOI":"10.18632\/oncotarget.10948"},{"key":"10.1016\/j.bmcl.2023.129384_b0130","doi-asserted-by":"crossref","unstructured":"Zimmer J, Tacconi EMC, Folio C, Badie S, Porru M, Klare K, et al. Targeting BRCA1 and BRCA2 deficiencies with G-quadruplex-interacting compounds. Mol. Cell. 2016; 61: 449\u2013460; PMC4747901.","DOI":"10.1016\/j.molcel.2015.12.004"},{"key":"10.1016\/j.bmcl.2023.129384_b0135","doi-asserted-by":"crossref","unstructured":"Ye FB, Hamza A, Singh T, Flibotte S, Hieter P, O'Neil NJ. A Multimodal Genotoxic Anticancer Drug Characterized by Pharmacogenetic Analysis in Caenorhabditis elegans. Genetics. 2020; 215: 609-621; PMC7337070.","DOI":"10.1534\/genetics.120.303169"},{"key":"10.1016\/j.bmcl.2023.129384_b0140","first-page":"PMC8105411","article-title":"Ubiquitin-mediated DNA damage response is synthetic lethal with G-quadruplex stabilizer CX-5461","volume":"11: 9812","author":"Masud","year":"2021","journal-title":"Sci Rep."},{"key":"10.1016\/j.bmcl.2023.129384_b0145","doi-asserted-by":"crossref","unstructured":"Yan S, Xuan J, Brajanovski N, Tancock MRC, Madhamshettiwar PB, Simpson KJ, et al. The RNA polymerase I transcription inhibitor CX-5461 cooperates with topoisomerase 1 inhibition by enhancing the DNA damage response in homologous recombination-proficient high-grade serous ovarian cancer. Br J Cancer. 2021; 124: 616\u2013627; PMC7851142.","DOI":"10.1038\/s41416-020-01158-z"},{"key":"10.1016\/j.bmcl.2023.129384_b0150","doi-asserted-by":"crossref","unstructured":"Zyner KG, Mulhearn DS, Adhikari S, Martinez Cuesta S, Di Antonio M, Erard N, et al. Genetic interactions of G-quadruplexes in humans. Elife. 2019; 8: ; PMC6615864.","DOI":"10.7554\/eLife.46793"},{"key":"10.1016\/j.bmcl.2023.129384_b0155","doi-asserted-by":"crossref","unstructured":"Huang WC, Tseng TY, Chen YT, Chang CC, Wang ZF, Wang CL, et al. Direct evidence of mitochondrial G-quadruplex DNA by using fluorescent anti-cancer agents. Nucleic Acids Res. 2015; 43: 10102\u201310113; PMC4666356.","DOI":"10.1093\/nar\/gkv1061"},{"key":"10.1016\/j.bmcl.2023.129384_b0160","doi-asserted-by":"crossref","unstructured":"Lee HC, Wang H, Baladandayuthapani V, Lin H, He J, Jones RJ, et al. RNA Polymerase I Inhibition with CX-5461 as a Novel Therapeutic Strategy to Target MYC in Multiple Myeloma. Br J Haematol. 2017; 177: 80\u201394; PMC5695568.","DOI":"10.1111\/bjh.14525"},{"key":"10.1016\/j.bmcl.2023.129384_b0165","doi-asserted-by":"crossref","unstructured":"Kim DW, Wu N, Kim YC, Cheng PF, Basom R, Kim D, et al. Genetic requirement for Mycl and efficacy of RNA Pol I inhibition in mouse models of small cell lung cancer. Genes Dev 2016; 30: 1289\u20131299; PMC4911928.","DOI":"10.1101\/gad.279307.116"},{"key":"10.1016\/j.bmcl.2023.129384_b0170","doi-asserted-by":"crossref","unstructured":"Hald OH, Olsen L, Gallo-Oller G, Elfman LHM, Lokke C, Kogner P, et al. Inhibitors of ribosome biogenesis repress the growth of MYCN-amplified neuroblastoma. Oncogene 2019; 38: 2800\u20132813; PMC6484764.","DOI":"10.1038\/s41388-018-0611-7"},{"key":"10.1016\/j.bmcl.2023.129384_b0175","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1038\/nature05953","article-title":"Non-transcriptional control of DNA replication by c-Myc","volume":"448","author":"Dominguez-Sola","year":"2007","journal-title":"Nature"}],"container-title":["Bioorganic & Medicinal Chemistry Letters"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960894X23002627?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960894X23002627?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,18]],"date-time":"2025-10-18T07:49:15Z","timestamp":1760773755000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0960894X23002627"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7]]},"references-count":35,"alternative-id":["S0960894X23002627"],"URL":"https:\/\/doi.org\/10.1016\/j.bmcl.2023.129384","relation":{},"ISSN":["0960-894X"],"issn-type":[{"value":"0960-894X","type":"print"}],"subject":[],"published":{"date-parts":[[2023,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A synthetic lethal approach to drug targeting of G-quadruplexes based on CX-5461","name":"articletitle","label":"Article Title"},{"value":"Bioorganic & Medicinal Chemistry Letters","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bmcl.2023.129384","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"129384"}}